Oncology Institute Guides Q1 Revenue $143.23M, Raises Full-Year Estimate to $647.84M
TOI•The Oncology Institute Inc forecasts Q1 2026 revenue of $143.23 million and an EPS loss of $0.08, with full-year estimates rising to $647.84 million revenue and a $0.23 EPS deficit. Analysts lifted full-year 2026 revenue projections by 1.8% over 90 days following the previous quarter’s 1.56% revenue beat and 33.33% EPS outperformance.
1. Q1 2026 Guidance
The Oncology Institute Inc forecasts Q1 2026 revenue of $143.23 million and an EPS loss of $0.08 per share as it prepares to report results.
2. Estimate Trend
Over the past 90 days, full-year 2026 revenue estimates have risen from $636.17 million to $647.84 million and EPS estimates improved from a $0.30 deficit to a $0.23 loss per share, indicating growing confidence in the company’s revenue trajectory.
3. Previous Quarter Performance
In Q4 2025, the company delivered revenue of $141.96 million, beating expectations by 1.56%, and posted an EPS loss of $0.06 per share, surpassing forecasts by 33.33%, which spurred an 8.40% share price gain in a single session.
4. Analyst Outlook
Analysts set an average one-year price target of $7.00 (implying 73.5% upside) while GF value estimates suggest a downside to $2.27, and the average brokerage recommendation remains an Outperform with a 1.8 rating.
